文献速递淋巴瘤造血干细胞移植与细胞治疗

高风险大B细胞淋巴瘤中应答适应、保留CAR-T的巩固放疗:RESTART前瞻性方案结果

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.
PubMed 文献 · Br J Haematol · 2026-07-03

RESTART前瞻性方案在高风险复发/难治大B细胞淋巴瘤中评估风险适应整合放疗与CAR-T。190例中55例(29%)接受放疗,照射野内局部控制率89%,巩固放疗后达92%。中位随访12.4个月,全队列1年PFS 57%、OS 71%;接受巩固放疗者尽管具高风险特征,1年PFS 54%、OS 95%,未见因对CAR-T负面影响导致系统性复发增加。

要点

  • 基于疾病分布与生物学分配放疗主导或系统桥接路径。
  • 输注后1个月DS 4-5或DS 3伴高危病灶者接受巩固放疗。
  • 巩固放疗采用保留CAR-T技术,局部控制好且未见系统复发增加。

核心结论

  • 应答适应、保留CAR-T的巩固放疗在高风险大B细胞淋巴瘤中可行且与良好结局相关。

研究设计与样本

  • 前瞻性RESTART方案,纳入190例复发/难治大B细胞淋巴瘤患者。
  • 按疾病分布和生物学分配至放疗主导路径A或系统桥接路径B。

主要发现

  • 190例中55例(29%)接受放疗,照射体积内局部控制率为89%。
  • 巩固放疗后照射体积内局部控制率为92%。
  • 中位随访12.4个月,全队列1年PFS为57%、OS为71%。
  • 接受巩固放疗者1年PFS为54%、OS为95%,未见因对CAR-T负面影响导致系统复发增加。

关键数值与推荐

  • 输注后1个月Deauville评分4-5,或Deauville评分3且基线高危病灶(≥5 cm和/或SUVmax≥15)者接受巩固放疗。
  • 巩固放疗于输注后6-8周 delivery,采用保留CAR-T技术以减少循环血剂量。

临床怎么用

  • 对CAR-T后早期应答不佳或基线高危的大B细胞淋巴瘤患者,可考虑应答适应巩固放疗。
  • 放疗应采用保留CAR-T技术以保护CAR-T细胞功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early relapse remains a major limitation of chimeric antigen receptor T cell (CAR-T) in relapsed or refractory large B-cell lymphoma (LBCL), particularly for high-risk disease or suboptimal early response. The prospective RESTART protocol evaluated a risk-adapted integration of radiotherapy (RT) with CAR-T. Patients were assigned to RT-dominant (Pathway A) or systemic bridging (Pathway B) based on disease distribution and biology. A key innovation was response-adapted consolidation RT for patients with Deauville score (DS) 4-5 at 1-month post-infusion, or DS 3 and baseline high-risk lesions (≥5 cm and/or maximum standard uptake value [SUVmax] ≥15). Consolidation RT was delivered 6-8 weeks post-infusion using CAR-T-sparing techniques to minimise circulating blood dose. Among 190 patients, 55 (29%) received RT. Local control within irradiated volumes was 89%, including 92% following consolidation RT. At a median follow-up of 12.4 months, the 1-year progression-free survival (PFS) and overall survival (OS) for the entire cohort were 57% and 71% respectively. Patients receiving consolidation RT, despite high-risk features, achieved a 1-year PFS of 54% and OS of 95% with no evidence of excess systemic relapse due to a negative effect on CAR-T. This protocol demonstrates that response-adapted, CAR-T-sparing consolidation RT is feasible and associated with favourable outcomes in high-risk LBCL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mikhaeel NG, Bouziana S, Northend M, et al. Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol. Br J Haematol. 2026. PMID: 42397071. doi:10.1111/bjh.70653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。